The latest attempt to spotlight Gilead Sciences and its business practices shifted to Congress in a sometimes contentious hearing on Truvada\'s cost. httpsbuff.ly2EeHY8dÂ

The latest attempt to spotlight Gilead Sciences and its business practices shifted to #Congress in a sometimes contentious hearing on Truvada's cost. https://buff.ly/2EeHY8d 

17:00 EDT 16 May 2019 | STAT

The latest attempt to spotlight Gilead Sciences and its business practices shifted to #Congress in a sometimes contentious hearing on Truvada's cost. https://buff.ly/2EeHY8d 

More From BioPortfolio on "The latest attempt to spotlight Gilead Sciences and its business practices shifted to #Congress in a sometimes contentious hearing on Truvada's cost. https://buff.ly/2EeHY8d "